Prophylaxis of recurrent urinary tract infections

被引:0
|
作者
Vahlensieck, W. [1 ]
Bauer, H. -W.
Piechota, H. J. [2 ]
Ludwig, M.
Wagenlehner, F. [3 ]
机构
[1] Kurpk Klin, Fachklin Urol, D-61231 Bad Nauheim, Germany
[2] Johannes Wesling Klinikum Minden, Klin Urol Padiat Urol & Urol Onkol, Minden, Germany
[3] Univ Giessen, UKGM GmbH, Klin & Poliklin Urol Kinderurol & Androl, Giessen, Germany
来源
UROLOGE | 2014年 / 53卷 / 10期
关键词
Lifestyle modifications; Antibiotic prophylaxis; Immunization; Alternative prophylactic measures; Long-term prophylaxis; ESCHERICHIA-COLI; DOUBLE-BLIND; LONG-TERM; RISK-FACTORS; PREVENTION; WOMEN; TRIAL; CRANBERRY; PROBIOTICS; JUICE;
D O I
10.1007/s00120-014-3562-9
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Recurrent urinary tract infections (rUTI), defined as a parts per thousand yen3 UTIs per year, mostly affect young and postmenopausal women. Treatable predisposing factors are rare. General recommendations to reduce rUTIs lower the recurrence rate by up to approximately two thirds. Continuous long-term prophylaxis (LP) with low dose antibiotics or single postcoital doses can reduce the recurrence rate of rUTIs to as low as 5%. According to the European Association of Urology guidelines nitrofurantoin, trimethoprim and co-trimoxazole are the first-line drugs and cephalosporins or fluoroquinolones should be restricted to specific indications. Oral and parenteral immunotherapy were found to be effective in several controlled studies for prevention of rUTIs and can be combined with acute antibiotic therapy. Vaginal prophylaxis with estriol has proven its positive effect without serious gynecological side effects and there is also increasing evidence that cranberries prevent rUTIs but the exact mode of this therapy remains to be defined. There are also other promising modalities, such as phytotherapeutics, mannose, urine acidification, influencing bacterial intestinal and vaginal flora and the general immune response by e.g. acupuncture and inpatient rehabilitation, the therapeutic value of which still has to be proven.
引用
收藏
页码:1468 / +
页数:7
相关论文
共 50 条
  • [21] Recurrent urinary tract infections
    Franco, AVM
    BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 2005, 19 (06) : 861 - 873
  • [22] Recurrent Urinary Tract Infections
    Eberhard, Ulrich H.
    DEUTSCHE ZEITSCHRIFT FUR AKUPUNKTUR, 2006, 49 (03): : 48 - 48
  • [23] Therapie und Prophylaxe rezidivierender HarnwegsinfekteTreatment and prophylaxis of recurrent urinary tract infections
    B. Banas
    B. K. Krämer
    Der Internist, 2005, 46 : 1360 - 1366
  • [24] Low dose oestrogen prophylaxis for recurrent urinary tract infections in elderly women
    Cardozo, L
    Benness, C
    Abbott, D
    BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1998, 105 (04): : 403 - 407
  • [25] EFFECTIVE POSTCOITAL QUINOLONE PROPHYLAXIS OF RECURRENT URINARY-TRACT INFECTIONS IN WOMEN
    PFAU, A
    SACKS, TG
    JOURNAL OF UROLOGY, 1994, 152 (01): : 136 - 138
  • [26] Recurrent urinary tract infections in women: risk factors, etiology, pathogenesis and prophylaxis
    Guglietta, Antonio
    FUTURE MICROBIOLOGY, 2017, 12 (03) : 239 - 246
  • [27] Comparison of sublingual therapeutic vaccine with antibiotics for the prophylaxis of recurrent urinary tract infections
    Lorenzo-Gomez, Maria F.
    Padilla-Fernandez, Barbara
    Garcia-Cenador, Maria B.
    Virseda-Rodriguez, Alvaro J.
    Martin-Garcia, Isidoro
    Sanchez-Escudero, Alfonso
    Vicente-Arroyo, Manuel J.
    Miron-Canelo, Jose A.
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2015, 5
  • [28] Recurrent and catheter-associated urinary tract infections. Prophylaxis and prevention
    Piechota, H.
    UROLOGE, 2017, 56 (06): : 734 - 745
  • [29] Antibiotic prophylaxis can prevent recurrent infection in children with urinary tract infections
    Wald, Ellen
    JOURNAL OF PEDIATRICS, 2010, 156 (05): : 856 - 857
  • [30] Newer quinolones in the long term prophylaxis of recurrent urinary tract infections (UTI)
    Krcméry, S
    Hromec, J
    Tvrdikova, M
    Hassan, M
    Gulla, D
    DRUGS, 1999, 58 (Suppl 2) : 99 - 102